JUNG-YIEN CHIENJANN-YUAN WANG2020-08-132020-08-1320171473-3099https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013834801&doi=10.1016%2fS1473-3099%2817%2930076-2&partnerID=40&md5=5fe1c145193e4882d0004330af0d7c3ahttps://scholars.lib.ntu.edu.tw/handle/123456789/512433[SDGs]SDG3ethambutol; isoniazid; pyrazinamide; rifampicin; antibiotic resistance; drug treatment failure; high risk patient; human; Letter; lung disease; lung tuberculosis; major clinical study; priority journal; relapse; sputum smear; Taiwan; treatment duration; treatment outcome; world health organizationletter10.1016/S1473-3099(17)30076-22-s2.0-85013834801